v3.19.3.a.u2
Other (Income)/Deductions - Net - Footnotes - Intangible Assets (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments $ 2,770 $ 3,100 $ 337
In Process Research and Development [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments 131    
In Process Research and Development [Member] | Multi-Antigen Vaccine For Spinal Fusion Surgery [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments   117  
AM Pharma BV [Member]      
Schedule of Intangible Assets [Line Items]      
Impairment of investment     43
Developed Technology Rights [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments 2,639   20
Developed Technology Rights [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments     127
Developed Technology Rights [Member] | Hospira [Member] | Sterile Injectable Pain Reliever [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments     124
Developed Technology Rights [Member] | Hospira [Member] | Generic Injectable Pain Reliever [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments     26
Developed Technology Rights [Member] | NextWave [Member] | Treatment Of Attention Hyperactivity Disorder [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments     $ 39
Developed Technology Rights [Member] | Biopharma Segment [Member] | Anacor [Member] | Eucrisa [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments 2,600    
Developed Technology Rights [Member] | Biopharma Segment [Member] | Anacor [Member] | Treatment For Toenail Fungus [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments 10    
Developed Technology Rights [Member] | Operating Segments [Member] | Biopharma Segment [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments 40    
Developed Technology Rights [Member] | Operating Segments [Member] | Biopharma Segment [Member] | Anacor [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments   31  
Developed Technology Rights [Member] | Operating Segments [Member] | Biopharma Segment [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments   2,600  
Licensing Agreements [Member] | Operating Segments [Member] | Biopharma Segment [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments   242  
In Process Research and Development [Member] | InnoPharma [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments 10 17  
In Process Research and Development [Member] | Biopharma Segment [Member] | AstraZeneca [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments 31    
In Process Research and Development [Member] | Operating Segments [Member] | Biopharma Segment [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments   $ 80  
Pfizer's Worldwide Research, Development And Medical [Member] | In Process Research and Development [Member] | Gene Therapies [Member]      
Schedule of Intangible Assets [Line Items]      
Intangible asset impairments $ 90